Search

… progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, … of ProQR. “In 2019 we shared positive Phase 1/2 data for sepofarsen in LCA10 and started the pivotal Phase 2/3 …

… title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 … investigator of the ProQR Phase 1/2 clinical trial of sepofarsen Professor and Director of Vitreoretinal Diseases …

… Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 … a significant improvement in vision after treatment with sepofarsen in a Phase 1/2 trial. These results strengthen our …

… far with the initiation of both the Phase 2/3 trial for sepofarsen and the proof of concept trial for QR-421a in … to patients.” Corporate Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 In April 2019, the …

… Results Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when … outcome of the primary analysis in the Illuminate trial of sepofarsen, we believe that the post-hoc analyses and the …

… The key deliverables for “ProQR Vision 2023” include: Sepofarsen (formerly QR-110) for Leber's congenital amaurosis … Officer at ProQR. “Clinical data for our lead program, sepofarsen, has presented strong potential for this medicine …

… investigator of the ProQR Phase 1/2 clinical trial of sepofarsen and Chairman and Head of the Department of … PhD, co-investigator of the PQ-110-001 clinical trial of sepofarsen and Research Professor of Ophthalmology at the …

… Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 … “As we prepare for results from our Phase 2/3 trial of sepofarsen, we are delighted to have Theresa join ProQR as …

… Western world have LCA10 because of this mutation. About Sepofarsen Sepofarsen (QR-110) is being evaluated in the pivotal Phase … splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting …

… targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial with regulators and provide an … have LCA10 because of this mutation. About s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy …